Topological analysis of blood differentially expressed genes in protein-protein interaction network in type 1 diabetes

authors:

avatar Nahid Safari-Alighiarloo , avatar Mohammad Taghizadeh , avatar Mohammad Tabatabaei , * , avatar Soodeh Shahsavari , avatar Saeed Namaki , avatar Soheila Khoda karim , avatar Mostafa Rezaei-Tavirani ORCID , avatar A. li Rashidy-Pour

Koomesh: Vol.18, issue 1; 86-94
published online: September 28, 2016
article type: Research Article
received: December 04, 2015
accepted: May 02, 2016

how to cite: Safari-Alighiarloo N, Taghizadeh M, Tabatabaei M, Shahsavari S, Namaki S, et al. Topological analysis of blood differentially expressed genes in protein-protein interaction network in type 1 diabetes. koomesh. 2016;18(1):e151149. 

Abstract

Introduction: Type 1 diabetes (T1D) results from autoimmune destruction of insulin-producing beta cells in pancreatic islets of Langerhans. To develop efficient treatments for T1D, it is required to identify suitable therapeutic markers. Systems biology offers approaches to better understanding of functional elements in the disease. Our aim was to investigate larger number of candidate markers in T1D by topological analysis of constructed PPI based on gene expression. Materials and Methods: In this study, gene expression profile of peripheral blood mononuclear cells from newly diagnosed type 1 diabetic children was prepared from Gene Expression Omnibus and analyzed to get differentially expressed genes. Then, these genes were mapped to PPIs data to construct related subnetwork. Five topological features were calculated by Cytoscape software.  Finally, degree, betweenness and closeness centrality features were utilized to identify candidate markers. Results: 2467 differentially expression genes were obtained by statistical analyzing of gene expression profile in which 1024 were upregulated and 1443 were downregulated. After mapping these genes on PPI network, there was constructed subnetwork with 949 nodes and 1776 edges. By topological analysis of the subnetwork, we determined high degree nodes (hub) and high betweenness nodes (bottleneck). Then, 9 hub-bottleneck proteins that were more central (high closeness centrality) in the subnetwork were identified and introduced as candidate markers. Conclusion: The obtained markers from network via systemic view can be considered as new diagnostic markers and potential therapeutic targets for T1D

References

  • 1.

    Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229.

  • 2.

    Van Belle TL, Coppieters KT, Von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011; 91: 79-118.

  • 3.

    Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994; 15: 516-542.

  • 4.

    Tanaka Y, Asakawa T, Asagiri K, Akiyoshi K, Hikida S, Mizote H. Nesidioblastosis treated successfully by 85% pancreatectomy. Kurume Med J 2004; 51: 99-103.

  • 5.

    Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nature Med 1999; 5: 601-604.

  • 6.

    Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, White PC. Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocr Metab 2007; 92: 3705-3711.

  • 7.

    Wang X, Jia S, Geoffrey R, Alemzadeh R, Ghosh S, Hessner MJ. Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J Immunol 2008; 180: 1929-1937.

  • 8.

    Kent SC, Chen Y, Clemmings SM, Viglietta V, Kenyon NS, Ricordi C, et al. Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J Immunol 2005; 175: 4458-4464.

  • 9.

    Ott PA, Berner BR, Herzog BA, Guerkov R, Yonkers NL, Durinovic-Bello I, et al. CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. J Immunol Methods 2004; 285: 223-235.

  • 10.

    Wu J, Vallenius T, Ovaska K, Westermarck J, Mkel TP, Hautaniemi S. Integrated network analysis platform for protein-protein interactions. Nature Methods 2009; 6: 75-77.

  • 11.

    Li M, Wu X, Wang J, Pan Y. Towards the identification of protein complexes and functional modules by integrating PPI network and gene expression data. BMC Bioinformatics 2012; 13: 109.

  • 12.

    Bapat SA, Krishnan A, Ghanate AD, Kusumbe AP, Kalra RS. Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer. Cancer Res 2010; 70: 4809-4819.

  • 13.

    Hindumathi V, Kranthi T, Rao S, Manimaran P. The prediction of candidate genes for cervix related cancer through gene ontology and graph theoretical approach. Mol BioSyst 2014; 10: 1450-1460.

  • 14.

    Zamanian-Azodi M, Rezaei-Tavirani M, Rahmati-Rad S, Hasanzadeh H, Rezaei-Tavirani M, Seyyedi SS. Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer. Gastroenterol Hepatol Bed Bench 2015; 8: 215-224.

  • 15.

    Zali H, Rezaei-Tavirani M. Meningioma protein-protein interaction Network. Arch Iran Med 2014; 17: 262.

  • 16.

    Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 2007; 3: e59.

  • 17.

    Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.

  • 18.

    Gautier L, Cope L, Bolstad BM, Irizarry RA. affyanalysis of affymetrix geneChip data at the probe level. Bioinformatics 2004; 20: 307-315.

  • 19.

    Rutherford A. Introducing ANOVA and ANCOVA: a GLM approach: Sage; 2001.

  • 20.

    Pedhazur EJ. Multiple regression in behavioral research: Explanation and prediction. 1997.

  • 21.

    Kerrien S, Aranda B, Breuza L, Bridge A, Broackes-Carter F, Chen C, Duesbury M, Dumousseau M, Feuermann M, Hinz U. The IntAct molecular interaction database in 2012. Nucleic Acids Res 2012; 40: D841-846.

  • 22.

    Ceol A, Aryamontri AC, Licata L, Peluso D, Briganti L, Perfetto L, Castagnoli L, Cesareni G. MINT, the molecular interaction database: 2009 update. Nucleic Acids Res 2010; 38: D532-539.

  • 23.

    Xenarios I, Salwinski L, Duan XJ, Higney P, Kim S-M, Eisenberg D. DIP, the database of interacting proteins: a research tool for studying cellular networks of protein interactions. Nucleic Acids Res 2002; 30: 303-305.

  • 24.

    Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.

  • 25.

    Bergholdt R, Brorsson C, Palleja A, Berchtold LA, Flyel T, Bang-Berthelsen CH, et al. Identification of novel type 1 diabetes candidate genes by integrating genome-wide association data, protein-protein interactions, and human pancreatic islet gene expression. Diabetes 2012; 61: 954-962.

  • 26.

    Feldman I, Rzhetsky A, Vitkup D. Network properties of genes harboring inherited disease mutations. Proc Natl Acad Sci U S A 2008; 105: 4323-4328.

  • 27.

    Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA. Protein-protein interaction networks (PPI) and complex diseases. Gastroenterol Hepatol Bed Bench 2014; 7: 17-31.

  • 28.

    Zhu M, Gao L, Li X, Liu Z, Xu C, Yan Y, et al. The analysis of the drug-targets based on the topological properties in the human protein-protein interaction network. J Drug Target 2009; 17: 524-532.

  • 29.

    Zali H, Zamanian-Azodi M, Rezaei-Tavirani M, Akbarzadeh-Baghban A. Protein drug targets of lavandula angustifolia on treatment of Rat Alzheimer's Disease. Iran J Pharm Res 2015; 14: 291.

  • 30.

    Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, Faria D, et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nature Biotechnol 2009; 27: 199-204.

  • 31.

    Jeong H, Mason SP, Barabsi A-L, Oltvai ZN. Lethality and centrality in protein networks. Nature 2001; 411: 41-42.

  • 32.

    Hase T, Tanaka H, Suzuki Y, Nakagawa S, Kitano H. Structure of protein interaction networks and their implications on drug design. PLoS Comput Biol 2009; 5: e1000550.

  • 33.

    Boumpas D, Tsokos G, Mann D, Eleftheriades E, Harris C, Mark G. Increased protooncogene expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1986; 29: 755-760.

  • 34.

    Laybutt DR, Weir GC, Kaneto H, Lebet J, Palmiter RD, Sharma A, Bonner-Weir S. Overexpression of c-Myc in -cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression, and diabetes. Diabetes 2002; 51: 1793-1804.

  • 35.

    Seko Y, Cole S, Kasprzak W, Shapiro BA, Ragheb JA. The role of cytokine mRNA stability in the pathogenesis of autoimmune disease. Autoimmun Rev 2006; 5: 299-305.

  • 36.

    Fukada T, Tonks NK. Identification of YB1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling. EMBO J 2003; 22: 479-493.

  • 37.

    Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nature Genet 2001; 27: 247-254.

  • 38.

    Zhou J, Kong C, Chen X. The short review on the studies of T cells receptors relate to type 1 diabetes. Diabetes Metabol Syndr 2014; 8: 252-254.

  • 39.

    Sjakste T, Paramonova N, Rumba-Rozenfelde I, Trapina I, Sugoka O, Sjakste N. Juvenile idiopathic arthritis subtype-and sex-specific associations with genetic variants in the PSMA6/PSMC6/PSMA3 gene cluster. Pediatr Neonatol 2014; 55: 393-403.

  • 40.

    Fu Y, Yan G, Shi L, Faustman D. Antigen processing and autoimmunity: evaluation of mRNA abundance and function of HLAlinked genesa. Ann N Y Acad Sci 1998; 842: 138-155.

  • 41.

    Ebato C, Uchida T, Arakawa M, Komatsu M, Ueno T, Komiya K, et al. Autophagy is important in islet homeostasis and compensatory increase of beta cell mass in response to high-fat diet. Cell Metab 2008; 8: 325-332.

  • 42.

    Fujitani Y, Kawamori R, Watada H. The role of autophagy in pancreatic -cell and diabetes. Autophagy 2009; 5: 280-282.

  • 43.

    Li Z, Qiao Z, Zheng W, Ma W. Network Cluster Analysis of ProteinProtein Interaction NetworkIdentified Biomarker for Type 2 Diabetes. Diabetes Technol Ther 2015; 17: 475-481.

  • 44.

    Eguchi K. Apoptosis in autoimmune diseases. Intern Med 2001; 40: 275-284.

  • 45.

    Yap T, Adib N, Coman D. Microduplication with autoimmune inflammatory arthritis. J Mol Genet Med 2015; 9: 1747-0862.

  • 46.

    Hemi R, Paz K, Wertheim N, Karasik A, Zick Y, Kanety H. Transactivation of ErbB2 and ErbB3 by tumor necrosis factor- and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins. J Biol Chemistry 2002; 277: 8961-8969##.